Intensity Therapeutics (NASDAQ:INTS – Get Free Report) issued its quarterly earnings data on Tuesday. Here are the key takeaways from Intensity Therapeutics’ conference call:Get Intensity Therapeutics alerts:INVINCIBLE-3 is preparing to restart enrollment at limited U.S. sites within the next few months after FDA review of a revised protocol; European restart preparations are also underway. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50. Intensity Therapeutics Company Profile(Get Free Report)Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Featured StoriesReceive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.